We haven't estimated the specific administrative costs of ramping up, in part because Canada, probably to the surprise of this committee, has dozens of public drug plans across the country in each province, territory, and at the federal level. All of them manage their own formularies; all of them make their own decisions, and all of them, should they participate with the pCPA, have to sign their own contracts. We have a tremendous amount of redundant infrastructure in the contract negotiations with drug manufacturers. Every drug listed on any provincial formulary in this country has to go through the formal listing process and increasingly requires a product listing agreement, or a utilization management agreement as they're known in Manitoba.
We are already doing this in large scale, but we are not doing it on behalf of the entire population. We are doing it on behalf of the select segments of the population that are beneficiaries of the existing public drug plans.
I think the pCPA is a tremendous example of the provinces voluntarily coming together to work together in order to increase their purchasing power. They are hindered by a couple of things, one of which is that the provincial drug plans fund less than 40% of drug costs in each province. That makes them a minority payer in the market place. That means that if they say yes to a drug, about 40% of the market is covered under that pCPA negotiated deal.